Advertisement
Singapore markets close in 1 hour 32 minutes

  • Straits Times Index

    3,278.65
    -9.10 (-0.28%)
     

  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     

  • Hang Seng

    17,658.08
    +373.54 (+2.16%)
     

  • FTSE 100

    8,134.97
    +56.11 (+0.69%)
     

  • Bitcoin USD

    64,410.61
    +129.32 (+0.20%)
     

  • CMC Crypto 200

    1,387.30
    -9.24 (-0.66%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • Dow

    38,085.80
    -375.12 (-0.98%)
     

  • Nasdaq

    15,611.76
    -100.99 (-0.64%)
     

  • Gold

    2,350.60
    +8.10 (+0.35%)
     

  • Crude Oil

    84.16
    +0.59 (+0.71%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • FTSE Bursa Malaysia

    1,575.40
    +6.15 (+0.39%)
     

  • Jakarta Composite Index

    7,103.97
    -51.32 (-0.72%)
     

  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

A Look at Sarepta Therapeutics’ Stock Performance

Kenneth Smith
Updated
A Look at Sarepta Therapeutics’ Stock Performance

Sarepta Therapeutics (SRPT) has a sponsored research and exclusive license option agreement with Genethon for advancing the latter’s microdystrophin gene therapy program. Sarepta also has a sponsored research and exclusive license option agreement with Duke University for advancing its gene-editing CRISPR/Cas9 technology for muscular dystrophy. Sarepta had submitted a marketing authorization application (or MAA) for eteplirsen to the European Medicines Agency (or EMA) in November 2016.

Continue reading